Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

Completed · Not applicable

Conditions studied: Meibomian Glands, Dry Eye Syndromes

In brief

This study will compare the safety and efficacy of TrueTear™ to standardized moist heat compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).

Key facts

Study ID

NCT03226769

Run by

Allergan

People needed

57

Starts

2017-07-26

Expected to finish

2017-12-12

Last updated by the study team

2020-10-30

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Dry eye disease or Meibomian Gland Disease as evaluated by Standard Participant Evaluation for Dryness (SPEED) score, Schirmer test, Tear film breakup time and other applicable objective measures at the Screening and Baseline Visits.
• Use of an artificial tear product, lid hygiene, omega-3 supplementation, antibiotics for the treatment of dry eye disease or Meibomian Gland Disease within one year of the Screening Visit.

You may not qualify if…

• Chronic or recurrent epistaxis, coagulation disorders or other conditions that may increase the risk of bleeding.
• History of nasal or sinus surgery.
• Vascularized polyp, deviated septum or severe nasal airway obstruction at the Screening visit.
• Intraocular and extraocular surgery in either eye within three months of the Screening Visit or refractive surgery within twelve months of the Screening Visit.
• Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic or active implanted electronic device in the head.

Where it is running

• Andover Eye Associates — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.